1. Search Result
Search Result
Results for "

B-cell receptor

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Screening Libraries

4

Biochemical Assay Reagents

9

Inhibitory Antibodies

2

Natural
Products

33

Recombinant Proteins

1

Isotope-Labeled Compounds

4

Antibodies

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160142

    Btk Cancer
    UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins and shows anti-cancer activity in murine xenograft models of TMD-8 cells .
    UBX-382
  • HY-NP006

    SPA

    Endogenous Metabolite Inflammation/Immunology
    Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .
    Protein A
  • HY-129390
    Orelabrutinib
    1 Publications Verification

    ICP-022

    Btk Cancer
    Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .
    Orelabrutinib
  • HY-111101

    IRAK Cancer
    AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
    AZ1495
  • HY-P99483

    AT 004; VT 007

    CD20 Adenosine Receptor Cancer
    Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
    Blontuvetmab
  • HY-136268

    Phosphatase Apoptosis Inflammation/Immunology
    AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth .
    AQX-435
  • HY-147308
    Zelenirstat
    2 Publications Verification

    PCLX-001

    N-myristoyltransferase Cancer
    Zelenirstat is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. Zelenirstat can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma .
    Zelenirstat
  • HY-P99761

    XmAb5871

    CD19 Apoptosis Inflammation/Immunology
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
    Obexelimab
  • HY-P99338

    CTL019

    CD19 Inflammation/Immunology Cancer
    Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .
    Tisagenlecleucel
  • HY-P99255

    CAT 8015; HA 22

    Antibody-Drug Conjugates (ADCs) CD22 Cancer
    Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .
    Moxetumomab pasudotox
  • HY-NP137

    Complement System Others
    NP-PE (Phycoerythrin) is an immune complex. The formation and transport of NP-PE (Phycoerythrin) depends on the complement system, specifically through the complement receptors CR1 and CR2. These receptors are expressed on the surface of B cells and help B cells capture and transport immune complexes. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes .
    NP-PE (Phycoerythrin)
  • HY-153357

    PROTACs Btk Cancer
    NRX-0492 is an orally active PROTAC-class BTK degrader. NRX-0492 catalyzes BTK ubiquitination and proteasome degradation (DC50 ≤ 0.2 nM, DC90 ≤ 0.5 nM) . NRX-0492 inhibits B cell receptor (BCR) mediated signaling, transcription programs, and chemokine secretion. NRX-0492 can bind non-covalently to the BTK binding domain and cereblon, which is an adapter protein in the E3 ubiquitin ligase complex . NRX-0492 consists of a target protein ligand (red part) BTK-IN-40 (HY-170324), an E3 ligase ligand (blue part) Thalidomide 5-fluoride (HY-W087383), and a PROTAC linker (black part) (3R)-3-Pyrrolidinemethanol (HY-60263). E3 ubiquitin ligase and linker can form Thalidomide 5-pyrrolidine-CHO (HY-49372A); the active control for the target protein ligand is BTK ligand 12 (HY-49421).
    NRX-0492
  • HY-153085

    CD19 Inflammation/Immunology Cancer
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR circRNA
  • HY-153084
    CD19 CAR mRNA (Mouse)
    1 Publications Verification

    CD19 Inflammation/Immunology Cancer
    CD19 CAR mRNA (Mouse) will express mouse CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR mRNA (Mouse)
  • HY-153084A

    CD19 Cancer
    CD19 CAR mRNA (Human) will express Human CD19 CAR protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 CAR is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 CAR mRNA (Human)
  • HY-147584

    Btk Inflammation/Immunology Cancer
    BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .
    BTK-IN-14
  • HY-147581

    Btk Inflammation/Immunology Cancer
    BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .
    BTK-IN-11
  • HY-109010
    Poseltinib
    1 Publications Verification

    HM71224; LY3337641

    Btk BMX Kinase Toll-like Receptor (TLR) Metabolic Disease
    Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .
    Poseltinib
  • HY-113134
    25-Hydroxycholesterol
    Maximum Cited Publications
    17 Publications Verification

    25-OHC

    Endogenous Metabolite Inflammation/Immunology
    25-Hydroxycholesterol (25-OHC) is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC50≈65 nM) and selective suppressor of IgA production by B cells.
    25-Hydroxycholesterol
  • HY-153234

    CD19 Liposome Inflammation/Immunology Cancer
    CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
    CD19 car circRNA-LNP
  • HY-153233

    CD19 Liposome Inflammation/Immunology Cancer
    CD19 car mRNA (Mouse)-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .
    CD19 car mRNA (Mouse)-LNP
  • HY-P990046

    Incagn-02385

    LAG-3 Inflammation/Immunology
    Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
    Tuparstobart
  • HY-165484

    Interleukin Related Inflammation/Immunology
    AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .
    AVP-13358
  • HY-160921

    SL65.0155 free base

    5-HT Receptor Neurological Disease
    Capeserod (SL65.0155 free base) is an agonist for serotonin receptor (5-HT receptor), with a Ki of 0.6 nM for 5-HT4 receptor. Capeserod enhances expression of phopshorilated cAMP-response element binding protein (p-CREB), vascular endothelium growth factor (VEGF), brain-derived neurotrophic factor (BDNF) and B cell lymphoma-2 (Bcl-2) proteins in hippocampus, and exhibits antidepressant-like efficacy in Wistar rats models .
    Capeserod
  • HY-P99487

    BR 3FC

    ADC Antibody Inflammation/Immunology
    Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .
    Briobacept
  • HY-15771A
    Tirabrutinib hydrochloride
    4 Publications Verification

    ONO-4059 hydrochloride; GS-4059 hydrochloride

    Btk Apoptosis Inflammation/Immunology Cancer
    Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib hydrochloride irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib hydrochloride can be used in studies of autoimmune diseases and hematological malignancies .
    Tirabrutinib hydrochloride
  • HY-15771
    Tirabrutinib
    4 Publications Verification

    ONO-4059; GS-4059

    Btk Apoptosis Inflammation/Immunology Cancer
    Tirabrutinib (ONO-4059) is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC50 of 6.8 nM. Tirabrutinib irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies .
    Tirabrutinib
  • HY-118374

    PI3K Akt Inflammation/Immunology
    AM-9635 is a selective PI3Kδ inhibitor with oral bioavailability, good in vitro and in vivo activity and pharmacodynamic properties. AM-9635 inhibits PI3Kδ-dependent B cell receptor-mediated AKT phosphorylation and suppresses the production of specific IgG and IgM antibodies in rats immunized with Aplysia leocyanin (KLH).
    AM-9635
  • HY-114732

    Adrenergic Receptor Others
    Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes .
    Procaterol
  • HY-113134S

    25-OHC-d6

    Isotope-Labeled Compounds Endogenous Metabolite Inflammation/Immunology
    25-Hydroxycholesterol-d6 (25-OHC-d6) is the deuterium labeled 25-Hydroxycholesterol. 25-Hydroxycholesterol is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC50≈65 nM) and selective suppressor of IgA production by B cells[1][2].
    25-Hydroxycholesterol-d6
  • HY-143423A

    MALT1 Inflammation/Immunology Cancer
    (S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1) .
    (S)-MALT1-IN-5
  • HY-113962
    7α,25-Dihydroxycholesterol
    2 Publications Verification

    7α,25-OHC

    EBI2/GPR183 Endogenous Metabolite Inflammation/Immunology
    7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells .
    7α,25-Dihydroxycholesterol
  • HY-150217

    ODN 10101

    Toll-like Receptor (TLR) HCV Infection Inflammation/Immunology
    CpG ODN 10101, a synthetic oligodeoxynucleotide (ODN),  is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 has antiviral and immunomodulatory properties that can influence chronic infection with HCV .
    CpG ODN 10101
  • HY-150217A
    CpG ODN 10101 sodium
    1 Publications Verification

    ODN 10101 sodium

    Toll-like Receptor (TLR) Infection
    CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .
    CpG ODN 10101 sodium
  • HY-150593

    IRAK Cancer
    IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC50 of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .
    IRAK4-IN-16
  • HY-13644

    15-Deoxyspergualin

    Others Others
    Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.
    Gusperimus

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: